A comparative study on the raft chemical properties of various alginate antacid raft-forming products

Dettmar, Peter W.; Gil‐González, Diana; Fisher, Jeanine; Flint, Lucy; Rainforth, Daniel; Potts, Mark

doi:10.1080/03639045.2017.1371737

Cited by 36 publications

(32 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of these analyses concluded that GDA was superior to all other competitor formulations. Moreover, GDA resulted in high porosity allowing neutralization of gastric acid to last for longer durations …”

Section: Resultsmentioning

confidence: 99%

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Yousaf

Nirwan

Smith

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GORD) is a common condition induced by unwarranted reflux of gastric and duodenal contents into the esophagus, and insufficient clearance of refluxate from it. Pharmaceutical formulations possessing raft‐forming capability offers an excellent alternative to conventional treatment options to treat uncomplicated GORD. These formulations typically contain a polymer, which performs distinctively upon contact with gastric acid and develops a foam‐like structure that can float on gastric contents. This review aims to feature research articles and patents that cover this topic. After undergoing a standardized literature search following preferred reporting items for systematic reviews and meta‐analyses guidelines, we have included 38 research articles and 18 patents describing the role of raft‐forming polymers in the treatment of GORD. This is a comprehensive review of formulation/testing of raft‐forming polymers. As expected, the majority of the studies focused on alginate; however, fewer studies have reported the use of pectin, xanthan gum, and raw psyllium fibers (husk). Moreover, it can be concluded from this comprehensive systematic review that a detailed characterization of raft‐forming formulations, type, and concentration of used active and inactive materials and different formulations factors are essential for the development of successful anti‐reflux raft‐forming formulations. © 2019 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2019, 136, 48012.

show abstract

Section: Resultsmentioning

confidence: 99%

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Yousaf

Nirwan

Smith

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…Pharmacokinetic parameters were estimated by using scientific application package Kinetica R version 4.1.1 (Thermo Electron Coorporation, USA). Values for maximum plasma concentration (C max , ng/mL) and time to reach the peak plasma concentration (t max , h) were determined directly from the average obtained data using Equations (5) and (6). Area under the plasma concentration time curve to time t (AUC 0-t , ng/mL.h) and area under the plasma concentration time curve to infinity (AUC 0-∞ , ng/mL.h) were calculated by mixed loglinear method using Equation 7.…”

Section: Discussionmentioning

confidence: 99%

“…The PPR1 formulation was unable to neutralize the acid, as shown in Figure 2C. In 2017, an interesting research article published by Dettmar et al 5 described the effect of raft structure on the neutralization profile of alginate raft-forming formulations. The PPR5 formulation containing 94% NCP showed a greater ANC value and 45 minute duration of neutralization profile as compared to the other formulations.…”

Section: Chemical Properties Of Raftmentioning

confidence: 99%

See 1 more Smart Citation

<p>Enhancement of Oral Bioavailability of Ibandronate Through Gastroretentive Raft Forming Drug Delivery System: In Vitro and In Vivo Evaluation</p>

Hanif¹,

Shah²,

Rasul³

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Bisphosphonates have very low bioavailability and cause irritation of the esophagus and stomach. This study was planned to improve the oral bioavailability of ibandronate through the formation of a raft in the stomach. Bisphosphonate-induced irritation of the esophagus and stomach is prevented by the formation of a raft. Materials and Methods: The nanostructured raft was developed through the use of nanosized citrus pectin (NCP). The particle size of NCP was measured by zeta sizer and SEM. The percentage of NCP and the neutralization profile of raft was studied. The ibandronate, polymers, and the developed formulation were characterized by FTIR, XRD, TGA, and DSC. The release of ibandronate was studied in 0.1 N HCl, 0.5 N HCl, 1 N HCl, and simulated gastric fluid (SGF) and a cell viability study was performed using Caco-2 cells. The PPR5 formulation and Bonish 150 mg tablets were selected as test and reference formulations, respectively, for pharmacokinetic study. Twelve healthy albino rats were taken and divided into two groups using a Latin square crossover design, and the blood samples were collected for 24 hours. Results: The SEM image showed that the particle size of NCP was 159 nm. The raft of PPR5 showed 94% NCP and 45 minutes duration of neutralization. The FTIR and XRD showed chemical stability and a uniform distribution of ibandronate in the raft. The TGA and DSC indicated the thermal stability of formulation. The release of 99.87% ibandronate at 20 minutes was observed in the SGF. The values of C max for the reference and test formulations were 493±0.237 ng/mL and 653±0.097 ng/mL, respectively. The AUC (0-t) of the reference and test formulations was 3708.25±3.418 ng/mL.h and 6899.25±3.467 ng/mL.h, respectively. Conclusion: The NCP has been successfully prepared from citrus pectin and has shown effective porous raft formation. The bioavailability of the ibandronate from newly developed PPR5 was higher than the already marketed formulation.

show abstract

“…It is recommended to use formulations without aluminum and to consider the sodium content (variable according to the different commercial products) for prolonged use, particularly in preterm newborns and in children with kidney disease [ 1 , 3 ]. Alginate formulations require three chemical reactions to take place simultaneously: transformation to alginic acid, sodium carbonate reacting to form carbon dioxide, and calcium releasing free calcium ions to bind with alginic acid providing strength to raft formation [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Alginate in Gastroesophageal Reflux in Infants

et al. 2018

View full text Add to dashboard Cite

BackgroundGuidelines are contradictory regarding the use of alginate in infants with persisting gastroesophageal reflux (GER). While The British National Institute for Health and Care (NICE) guidelines consider alginate as a treatment option, the guidelines of the European and North-American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN, NASPGHAN) do not recommend alginates.AimsWe assessed the efficacy of alginate to reduce GER episodes in infants.MethodsIn a prospective, observational study, we consecutively enrolled all infants referred for pH-multiple intraluminal impedance (pH-MII) recording because of persisting GER symptoms not responsive to behavior and dietetic modifications. A 48-h pH-MII was performed in all infants; a baseline recording was performed during the first 24 h while magnesium or sodium alginate was administered during the second 24 h. The primary endpoint was the difference in the total number of GER episodes per 24 h between the baseline day and the second day during which the alginate was administered. The secondary outcome was the difference in symptoms between each period. We also compared other pH-MII data from before and during alginate administration.ResultsWe recruited 43 infants (median age 68 days, range 25–306); three pH-MII tracings were excluded because of artifacts. The median number of all MII reflux episodes was significantly reduced during alginate administration (76.0 vs 69.5; p < 0.001). Crying-fussiness, cough and regurgitation episodes all significantly improved during alginate administration (p = 0.00012; p = 0.005 and p = 0.04, respectively). The following MII parameters also decreased during the alginate administration: acid (19.0 vs 14.5; p < 0.04), non-acid (52.0 vs 49.5; p < 0.004), proximal GER episodes (46.0 vs 41.4; p < 0.007), and bolus exposure index (1.9 vs 1.6; p = 0.002). At least three out of seven pH-MII parameters decreased by > 10% during the alginate period in 31/40 infants (77.5%), without a significant difference between magnesium and sodium alginate.ConclusionThese results suggest that alginate significantly decreases the number and extension of both acid and non-acid reflux episodes and associated symptoms in infants.Electronic supplementary materialThe online version of this article (10.1007/s40272-018-0314-0) contains supplementary material, which is available to authorized users.

show abstract

A comparative study on the raft chemical properties of various alginate antacid raft-forming products

Cited by 36 publications

References 18 publications

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

<p>Enhancement of Oral Bioavailability of Ibandronate Through Gastroretentive Raft Forming Drug Delivery System: In Vitro and In Vivo Evaluation</p>

The Effect of Alginate in Gastroesophageal Reflux in Infants

Contact Info

Product

Resources

About